Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

MDMA

In Canada, the prevalence of depression and mental health disorders has shown a worrying increase. According to data from 2022, over 5 million Canadians, accounting for 18% of the…
There’s no better due diligence in the psychoactive drug space than Health Canada. Loads of pharma companies have investor decks that promise they’ll one day be in the psychedelics…
A few weeks back, in what has become a seminal Equity.Guru piece about the quickly legalizing safe supply drug space, I tore into PharmaDrug (PHRX.C), which was lurching into…
Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the…
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on…
I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl…
Expanding Horizons $20.677M Market Capitalization Optimi Health Corp. (OPTI.C) announced today that it has entered into a supply agreement with SABI Mind. According to the terms of the agreement,…
Numinus Wellness (NUMI.T) has moved into the implementation part of their MDMA-assisted psychotherapy trial for post-traumatic stress disorder (PTSD) clinical trial by enrolling and dosing its first volunteer. Numinus…
The psychedelics sector is looking ready for a reversal. We are just waiting for the breakout confirmation. Earlier this week, we discussed how the bottom is in for cannabis…
Back in October, Zuckerberg, seeing plunging user numbers and fading growth, desperately renamed Facebook, once the world’s foremost purveyor of misinformation and unethical aggregator of personal data, to Meta,…